Children’s National’s Stephan Ladisch, MD, Research Targets Tumor Self-Protection September 24, 2014

Allergy testing samples; pediatric allergy and immunology testing for children in Washington D C, Maryland and Virgina.

Washington, DC -- Stephan Ladisch, MD, a hematologist-oncologist  in the Center for Cancer and Immunology Research at Children’s National Health System, and his laboratory have uncovered a mechanism by which tumors protect themselves from being eliminated by the body’s normal immune defenses. 

The result is a discovery that may define a new way to reduce tumor growth. This can be a promising approach to improve cancer treatment, with “broad implications” for treatment of many tumors, Dr. Ladisch writes in Cancer Research, a journal of the American Association of Cancer Research.  

For over three decades, first at University of California, Los Angeles (UCLA) and now at Children’s National, Ladisch has focused on studying tumor-host interactions and the tumor production of certain critical cell surface molecules, gangliosides. “The biological role of gangliosides has been my research focus over my career,” he says. Dr. Ladisch says the findings have implications for the pathogenesis of neuroectodermal and other tumors that affect children, as well as those that strike adults.

Many different types of tumors make and release large quantities of these ganglioside molecules. Their production by tumor cells is one of the tools tumors use to protect themselves, and this is a specific target of our work,” says Ladisch, also a Professor of Pediatrics and Biochemistry/Molecular Biology at the George Washington University School of Medicine. 

Gangliosides are molecules that reside in the plasma membrane of the cell. When these molecules are released by tumor cells, they bathe the tumor site and have been shown to drive tumor growth, and block the immune response. Other cells, known as myeloid suppressor cells, also can enhance tumor growth and “block the immune response that normally might be able to eliminate it,” says Dr. Ladisch.

In this study, the important finding is that when ganglioside production by tumor cells was eliminated, the generation of these suppressor cells was markedly reduced, the immune response was enhanced, and the tumors grew much more slowly, Dr. Ladisch says. 

“Because there have been significant gaps in knowledge of how tumors escape immune control, our findings that establish tumor gangliosides as an important immune evasion factor have potential broad significance because rapid ganglioside synthesis and shedding characterizes many tumor types,” Dr. Ladisch added. 

Ladisch says: “One could imagine that by applying this finding, for example by developing a drug that inhibits the production of these ganglioside molecules, a cascade of events could begin: You could combine such an approach, disabling the tumor’s ability to adapt itself and grow in the body, together with other treatments to potentially eliminate the cancer.”

Contact: Joe Cantlupe at 202-476-4500.

# # #

About Children’s National Health System

Children’s National Health System, based in Washington, DC, has been serving the nation’s children since 1870. Children’s National is ranked in the top 20 in every specialty evaluated by U.S. News & World Report; one of only four children’s hospitals in the nation to earn this distinction. Designated a Leapfrog Group Top Hospital and a two-time recipient of Magnet® status, this pediatric academic health system offers expert care through a convenient, community-based primary care network and specialty outpatient centers. Home to the Children’s Research Institute and the Sheikh Zayed Institute for Pediatric Surgical Innovation, Children’s National is one of the nation’s top NIH-funded pediatric institutions. Children’s National is recognized for its expertise and innovation in pediatric care and as a strong voice for children through advocacy at the local, regional and national levels. For more information, visit, or follow us on Facebook and Twitter.

Latest Tweets